| Market Cap | 8.86M | P/E | - | EPS this Y | 70.00% | Ern Qtrly Grth | - |
| Income | -12.04M | Forward P/E | -2.96 | EPS next Y | 46.70% | 50D Avg Chg | -29.00% |
| Sales | 14.02M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -50.00% |
| Dividend | N/A | Price/Book | 1.26 | EPS next 5Y | - | 52W High Chg | -90.00% |
| Recommedations | 2.00 | Quick Ratio | 1.10 | Shares Outstanding | 4.77M | 52W Low Chg | 29.00% |
| Insider Own | 4.24% | ROA | -57.00% | Shares Float | 2.79M | Beta | 7.71 |
| Inst Own | 12.57% | ROE | -284.96% | Shares Shorted/Prior | 63.71K/87.39K | Price | 0.30 |
| Gross Margin | 60.07% | Profit Margin | -85.90% | Avg. Volume | 247,695 | Target Price | 7.42 |
| Oper. Margin | -47.76% | Earnings Date | Nov 12 | Volume | 195,279 | Change | 2.14% |
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
| Ascendiant Capital | Buy | Aug 20, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Huntsman Ronald Kirk | Chief Executive Offi.. Chief Executive Officer | Jun 20 | Buy | 0.53 | 14,000 | 7,420 | 86,521 | 06/20/23 |
| Huntsman Ronald Kirk | Chief Executive Offi.. Chief Executive Officer | Jun 15 | Buy | 0.52 | 15,021 | 7,811 | 72,521 | 06/20/23 |
| Huntsman Ronald Kirk | Chief Executive Offi.. Chief Executive Officer | Jun 14 | Buy | 0.49 | 10,000 | 4,900 | 57,500 | 06/15/23 |
| Huntsman Ronald Kirk | Chief Executive Offi.. Chief Executive Officer | Dec 23 | Buy | 0.50 | 20,000 | 10,000 | 47,500 | 12/28/22 |
| Huntsman Ronald Kirk | Chief Executive Offi.. Chief Executive Officer | May 31 | Buy | 1.93 | 12,000 | 23,160 | 27,500 | 06/03/22 |